Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27747569 | 1.00 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL24715426 | 1.00 | TP53 (0.52) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL28846887 | 0.88 | — | — | |
| SCHEMBL22624869 | 0.80 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL12631952 | 0.78 | SLC6A2 (0.48) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL12631967 | 0.78 | SLC6A2 (0.48) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4000568 | 0.78 | CPN1 (0.36) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20095863 | 0.77 | KMT2A (0.43) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20096006 | 0.77 | KMT2A (0.43) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20095865 | 0.77 | KMT2A (0.43) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979356-B1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PROD INC (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-101346382-B | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | PFIZER PROD INC | 2011-07-06 | — | — | CN | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| CN-101346382-A | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors | PFIZER PROD INC (US) | 2009-01-14 | — | — | CN | disclosed |
| EP-1979356-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007072153-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | TP53 1444/4885KDM4E 1361/4885GMNN 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.